Middle east and asia pacific cell and gene therapy market

Q: Which region holds the largest market share in the market?

Asia Pacific holds the largest market share in the market. Read more

Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Mar 2022
CMI4981
425 Pages
Excel & Pdf
Biotechnology

Summary

Plasmid DNA is becoming increasingly important in clinical research for gene therapy and genetic vaccine applications. Good manufacturing practice (GMP)-grade plasmid DNA is required for direct gene transfer into humans. The same is true if the drug material contains a genetically modified cell, such as chimeric antigen receptor (CAR) T cells, which are employed along with the plasmids present in the drug substance.

In many circumstances, however, high quality grade plasmid DNA is approved as a starting material for GMP synthesis of mRNA or viral vectors (lentiviral vectors, adeno-associated virus vectors, and so on). AAV (adeno associated viruses) vectors support the production of protein, leading to therapeutic effect, without permanently altering the patient’s DNA. Lentiviral vectors are retroviruses used to introduce a functional copy of a gene to the patient’s extracted hematopoietic stem cells with a longer-term therapeutic effect.

Middle East and Asia Pacific cell and gene therapy market is estimated to be valued at US$ 2,616.8 million in 2021 and is expected to exhibit a CAGR of 17.3% over the forecast period (2021-2028).

Figure 1. Middle East and Asia Pacific Cell and Gene Therapy Market Share (%), in Terms of Value, By Region, 2021

Increasing launch and approval of novel gene therapies for the treatment of various rare diseases is expected to derive the market growth

In June 2017, Horama S.A. a biotechnology company announced that U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HORARLBP1. A gene replacement therapy Moreover, HORARLBP1 is developed for the treatment of retinitis punctata albescens and retinitis pigmentosa caused by mutations in the RLBP1 gene.

Middle East and Asia Pacific Cell and Gene Therapy Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 2,616.8 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	17.3%	2028 Value Projection:	US$ 8,015.1 Mn
Geographies covered:	Middle East: Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, and Rest of Middle East Asia Pacific: South East Asia (Philippines, Malaysia, Singapore, Thailand, Vietnam and Rest of South East Asia), Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific
Segments covered:	By Therapy Type: Cell Therapy (Stem Cells, T Cells, Dendritic Cells, NK Cells), Gene Therapy (Germline Gene Therapy, Somatic Gene Therapy) By Indication: Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, Others By Technology: Lentiviral Vector, Plasmid DNA, AAV
Companies covered:	Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd
Growth Drivers:	Increasing approval and launch of novel gene therapies for treatment of various rare diseases Robust Pipeline Of Cell And Gene Therapies
Restraints & Challenges:	Unfavorable reimbursement policies for cell and gene therapy products Manufacturing issues limiting the availability of cell and gene therapy products at treatment centers

Figure 2. Middle East and Asia Pacific Cell and Gene Therapy Market Share (%), by Therapy Type, 2021

Middle East and Asia Pacific Cell and Gene Therapy Market – Impact of Coronavirus (COVID-19) Pandemic – Impact on Drug Development and Clinical Trials

While the healthcare industry continues to focus on the development of COVID-19 vaccines and therapies, the COVID-19 crisis had a significant impact on clinical trials in many therapy areas such as oncology, cardiovascular, and others.

Research programs and preclinical operations have been affected across the cell and gene therapies (CGTs) sector, as pharmaceutical businesses have restricted the number of individuals working on-site to keep them safe and comply with regulatory instructions.

The increasing demand for COVID-19-related laboratory consumables such as personal protective equipment and reagents has hampered the research and preclinical development, resulting in supply chain constriction.

Cell and gene therapies (CGTs) are at the forefront of medical advancements in the treatment of serious diseases such as cancer, cardiovascular diseases, and others. Many more CGTs are currently being developed.

Middle East and Asia Pacific Cell and Gene Therapy Market: Restraint

Factor such as unfavorable reimbursement policies for cell and gene therapy products is expected to hamper the market growth over the forecast period.

Kymriah is a genetically-modified autologous T-cell immunotherapy has listed price of US$ 475,000 for patients with acute lymphocytic leukemia and US$ 373,000 for patients with large B-cell lymphoma; whereas, Yescarta has a listed price of US$ 373,000. Indicated for the treatment of adults with follicular lymphoma or certain types of large B-cell lymphoma Therefore, treatment with such a high price requires government support, in terms of reimbursement policy for a better adoption rate.

However, cell and gene therapy has witnessed multiple setbacks from regulatory authorities in charge of reimbursement policies, which is expected to hinder growth of the market.

Key Players

Major players operating in the Middle East and Asia Pacific cell and gene therapy market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.

Table of Content

Table of Contents

*Browse 20 market data tables and 26 figures on "Middle East and Asia Pacific Cell and Gene Therapy Market” – forecast to 2028

Segmentation

Detailed Segmentation:

Middle East and Asia Pacific Cell and Gene Therapy Market, By Therapy Type:
- Cell Therapy
  - Stem Cells
  - T Cells
  - Dendritic Cells
  - NK Cells
- Gene Therapy
  - Germline Gene Therapy
  - Somatic Gene Therapy
Middle East and Asia Pacific Cell and Gene Therapy Market, By Indication:
- Dermatology
- Musculoskeletal
- Oncology
- Immunology
- Cardiology & Neurology
- Others
Middle East and Asia Pacific Cell and Gene Therapy Market, By Technology:
- Lentiviral Vector
- Plasmid DNA
- AAV
Middle East and Asia Pacific Cell and Gene Therapy Market, By Region:
- Middle East
  - By Therapy Type
    - Cell Therapy
      - Stem Cells
      - T Cells
      - Dendritic Cells
      - NK Cells
    - Gene Therapy
      - Germline Gene Therapy
      - Somatic Gene Therapy
  - By Indication
    - Dermatology
    - Musculoskeletal
    - Oncology
    - Immunology
    - Cardiology & Neurology
    - Others
  - By Technology
    - Lentiviral Vector
    - Plasmid DNA
    - AAV
  - By Country
    - Kingdom of Saudi Arabia
    - UAE
    - Israel
    - Iran
    - Jordan
    - Rest of Middle East
- Asia Pacific
  - By Therapy Type
    - Cell Therapy
      - Stem Cells
      - T Cells
      - Dendritic Cells
      - NK Cells
    - Gene Therapy
      - Germline Gene Therapy
      - Somatic Gene Therapy
  - By Indication
    - Dermatology
    - Musculoskeletal
    - Oncology
    - Immunology
    - Cardiology & Neurology
    - Others
  - By Technology
    - Lentiviral Vector
    - Plasmid DNA
    - AAV
  - By Country
    - South East Asia
      - Philippines
      - Malaysia
      - Singapore
      - Thailand
      - Vietnam
      - Rest of South East Asia
    - Taiwan
    - Hong Kong
    - Macau
    - Japan
    - South Korea
    - India
    - Australia
    - China
    - Rest Of Asia pacific

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the Middle East and Asia Pacific Cell and Gene Therapy Market during the forecast period (2021-2028)?

The Middle East and Asia Pacific cell and gene therapy market size is estimated to be valued at US$ 2,616.8 million in 2021 and is expected to exhibit a CAGR of 17.3% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing launch and approval of novel gene therapies for the treatment of various rare diseases and robust pipeline of products are expected to drive the market growth over the forecast period.

Which is the leading therapy type segment in the market?

Cell therapy segment is expected to hold major market share.

Which region holds the largest market share in the market?

Asia Pacific holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factor hampering growth of the market include unfavorable reimbursement policies for cell and gene therapy products.

Which are the major players operating in the market?

Major players operating in the market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.